hEPO Biopump production and number of implanted dermal cores
Patient ID no. . | Dose† . | Treatment group . | Patient weight (kg) . | Glucose consumption, μg/day/BP . | No. of Biopumps implanted . |
|---|---|---|---|---|---|
| H001 | 16.3/1369 | LD | 84.0 | 360.41 ± 131.34 | 7 |
| H002 | 17.5/1407 | LD | 80.5 | 336.49 ± 169.82 | 2 |
| H006 | 19.9/1331 | LD | 67.0 | 780.49 ± 87.66 | 1 |
| H007 | 19.7/1242 | LD | 63.0 | 320.18 ± 193.97 | 2 |
| H008 | 63.3/4843 | HD | 76.5 | 478.38 ± 145.00 | 6 |
| H009 | 62.8/4644 | HD | 74.0 | 463.10 ± 107.65 | 3 |
| H010 | 64.3/4631 | HD | 72.0 | 640.41 ± 173.01 | 3 |
| H011 | 19.6/1234 | LD | 63.0 | 482.42 ± 51.46 | 4 |
| H012 | 64.2/6928 | HD | 108.0 | 791.64 ± 74.14 | 5 |
| H013 | 64.0/4545 | HD | 71.0 | 626.70 ± 128.59 | 3 |
Patient ID no. . | Dose† . | Treatment group . | Patient weight (kg) . | Glucose consumption, μg/day/BP . | No. of Biopumps implanted . |
|---|---|---|---|---|---|
| H001 | 16.3/1369 | LD | 84.0 | 360.41 ± 131.34 | 7 |
| H002 | 17.5/1407 | LD | 80.5 | 336.49 ± 169.82 | 2 |
| H006 | 19.9/1331 | LD | 67.0 | 780.49 ± 87.66 | 1 |
| H007 | 19.7/1242 | LD | 63.0 | 320.18 ± 193.97 | 2 |
| H008 | 63.3/4843 | HD | 76.5 | 478.38 ± 145.00 | 6 |
| H009 | 62.8/4644 | HD | 74.0 | 463.10 ± 107.65 | 3 |
| H010 | 64.3/4631 | HD | 72.0 | 640.41 ± 173.01 | 3 |
| H011 | 19.6/1234 | LD | 63.0 | 482.42 ± 51.46 | 4 |
| H012 | 64.2/6928 | HD | 108.0 | 791.64 ± 74.14 | 5 |
| H013 | 64.0/4545 | HD | 71.0 | 626.70 ± 128.59 | 3 |
BP indicates Biopump.
*Patients were assigned to a low-dose (LD) and high-dose (HD) treatment group.
Dose is presented as IU per kg per day/IU total